Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Extended Alar Contour Grafts in Rhinoplasty

Published: Wed, 13 Dec 2017 12:00:00 EST
The authors discuss the extended alar contour graft as another technique in the open approach to rhinoplasty.
Plastic and Reconstructive Surgery

Inflammation After Cataract and Complex Ocular Surgeries

Published: Wed, 13 Dec 2017 12:00:00 EST
Which management strategies for postoperative ocular inflammation are most effective?
The British Journal of Ophthalmology

Discharge Plans for Geriatric Inpatients With Delirium

Published: Wed, 13 Dec 2017 12:00:00 EST
Are outpatient providers to geriatric patients with delirium who are discharged on a new antipsychotic being properly provided with instructions for discontinuation?
Journal of the American Geriatrics Society

Challenges and New Opportunities for GxE Interaction Studies

Published: Wed, 13 Dec 2017 12:00:00 EST
How does the interaction of genes and environment contribute to our understanding of disease in the human population? Read about the emerging field of gene-environment interaction (GxE) in this review.
American Journal of Epidemiology
Displaying results 5-8 (of 20)
 1 - 2 - 3 - 4 - 5 


Ex-Dezima executives scoop €25M for midphase NASH trial

Published: Tue, 12 Dec 2017 11:35:30 +0000
NorthSea Therapeutics has raised €25 million ($29 million) to put a NASH drug through phase 2b. The round reunites some of the executives and investors who helped Dezima and NASH startup Akarna to takeovers by Amgen and Allergan, respectively.

Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint

Published: Mon, 11 Dec 2017 14:23:54 +0000
With breakthrough designation from the FDA and priority medicine status in the EU, expectations for Roche’s antibody-drug conjugate for non-Hodgkin lymphoma polatuzumab vedotin are running pretty high. Phase 2 data presented at ASH 2017 suggests that optimism could be justified.

Adding precision to multiple myeloma treatments with DNA sequencing: ASH

Published: Mon, 11 Dec 2017 14:04:54 +0000
At the annual American Society of Hematology (ASH) meeting, oncologists at the Dana-Farber Cancer Institute demonstrated how simple blood tests may make it possible to use DNA sequencing to track how multiple myeloma is progressing in individual patients—and whether they're becoming resistant to the therapies they’re given.

Syros tanks on single-digit response rate in AML, MDS trial 

Published: Mon, 11 Dec 2017 13:33:07 +0000
Syros Pharmaceuticals has emerged from the weekend of ASH data drops in a battered state after it was unable to put a positive spin on an initial look at phase 2 data. The clinical trial recorded one partial or complete response among the 48 evaluable patients, wiping 50% off Syros’ stock.
Displaying results 5-8 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy